Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

2021 ◽  
Vol 157 ◽  
pp. 250-258
Author(s):  
Alice Baggi ◽  
Pietro Quaglino ◽  
Marco Rubatto ◽  
Roberta Depenni ◽  
Michele Guida ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Real World ◽  
Locally Advanced ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Real World Data ◽  
World Data

scholarly journals CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma

2020 ◽  
Vol 16 (4) ◽  
pp. 11-19 ◽  
Author(s):  
Michael R Migden ◽  
Sunandana Chandra ◽  
Guilherme Rabinowits ◽  
Chieh-I Chen ◽  
Jigar Desai ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Real World ◽  
Locally Advanced ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Epidemiology Study ◽  
Curative Surgery ◽  
Registration Number ◽  
Us Fda

In 2018, cemiplimab-rwlc became the first systemic treatment approved by the US FDA for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. In 2019, conditional approvals were granted by Health Canada and the European Commission for the same indications. Limited data exist pertaining to the clinical characteristics, disease progression and survivorship of patients with advanced CSCC in real-world clinical practice. CemiplimAb-rwlc Survivorship and Epidemiology (CASE) is a prospective Phase IV, noninterventional, survivorship and epidemiology study that will enroll patients with advanced CSCC who have recently initiated or who plan to receive cemiplimab in a real-world setting. Trial registration number: NCT03836105.

Sign in / Sign up

Export Citation Format

Share Document